What emerging trends in the FDA’s most coveted designations might tell us
Marked shifts in the pursuit and grant of high-order designations raise fascinating questions. What factors might be driving the sharp downturns in CDER breakthrough designations? And does the sharp post-pandemic upturn in high-order designations by CBER represent a shifting of enthusiasm in favor of advanced therapies? This report, analyzing recent data from the FDA, gives critical insights into market shifts in high-order designations and what it might mean for drug developers.
Related Insights
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Video
Overcoming asset transfer challenges during a merger and acquisition (M&A)
Oct 20, 2021
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Webinar
Accelerated Early Phase Decision-Making – Insider Insights to Speed Development
Jan 7, 2025
Playbook
Early-phase development strategies for navigating regulatory complexity in the EU
Apr 29, 2024
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Blog
Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development
Jan 22, 2025
Blog
Overcoming risks in Phase 3 trials to accelerate time to market
Jan 22, 2025
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Playbook
Streamlining development in the EU: Strategies for smoother CTA submissions
Feb 27, 2025
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Related Insights
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Video
Overcoming asset transfer challenges during a merger and acquisition (M&A)
Oct 20, 2021
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Webinar
Accelerated Early Phase Decision-Making – Insider Insights to Speed Development
Jan 7, 2025
Playbook
Early-phase development strategies for navigating regulatory complexity in the EU
Apr 29, 2024
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Blog
Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development
Jan 22, 2025
Blog
Overcoming risks in Phase 3 trials to accelerate time to market
Jan 22, 2025
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Playbook
Streamlining development in the EU: Strategies for smoother CTA submissions
Feb 27, 2025
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021